J Med Microbiol Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Spigaglia, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spigaglia, P.
Agricola
Right arrow Articles by Spigaglia, P.
J Med Microbiol 57 (2008), 784-789; DOI: 10.1099/jmm.0.47738-0
© 2008 Society for General Microbiology
ISSN 1473-5644

Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe

Patrizia Spigaglia1, Fabrizio Barbanti1, Paola Mastrantonio1, Jon S. Brazier2, Frédéric Barbut3, Michel Delmée4, Ed Kuijper5, Ian R. Poxton6 and on behalf of the European Study Group on Clostridium difficile (ESGCD){dagger}

1 Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy

2 Anaerobe Reference Laboratory, NPHS Microbiology Cardiff, University Hospital of Wales, Cardiff CF14 4XW, UK

3 Microbiology Unit, Hôpital Saint-Antoine, Paris, France

4 Microbiology Unit, Université Catholique de Louvain, Bruxelles, Belgium

5 Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands

6 Department of Medical Microbiology, Edinburgh University, Edinburgh, UK

Correspondence
Paola Mastrantonio
paola.mastrantonio{at}iss.it

Received 31 October 2007
Accepted 25 January 2008

The European Study Group on Clostridium difficile (ESGCD) conducted a prospective study in 2005 to monitor and characterize C. difficile strains circulating in European hospitals, collecting 411 isolates. Eighty-three of these isolates, showing resistance or intermediate resistance to moxifloxacin (MX), were selected for this study to assess susceptibility to other fluoroquinolones (FQs) and to analyse the gyr genes, encoding the DNA gyrase subunits GyrA and GyrB. Twenty MX-susceptible isolates from the surveillance study were included for comparison. Overall, one amino acid substitution in GyrA (Thr82 to Ile) and four different substitutions in GyrB (Ser416 to Ala, Asp426 to Asn, Asp426 to Val and Arg447 to Lys) were identified. A high level of resistance (MIC ≥32 µg ml–1) to MX, ciprofloxacin (CI), gatifloxacin (GA) and levofloxacin (LE) was found in 68 isolates showing the amino acid substitution Thr82 to Ile in GyrA, in eight isolates with the substitutions Thr82 to Ile in GyrA and Ser416 to Ala in GyrB, in two isolates showing the substitution Asp426 to Asn in GyrB and in one isolate with Asp426 to Val in GyrB. The remaining four isolates showed high MICs for CI and LE, but different MIC levels for MX and GA. In particular, intermediate levels of resistance to MX were shown by two isolates, one with the substitution Thr82 to Ile in GyrA, and one showing Asp426 to Asn in GyrB. The substitution Arg447 to Lys in GyrB was found in two strains resistant to MX, CI and LE but susceptible to GA. No substitutions in GyrA were found in the FQ-susceptible strains, whereas two strains showed the amino acid change Ser416 to Ala in GyrB. Thr82 to Ile was the most frequent amino acid change identified in the C. difficile isolates examined. In contrast to previous observations, 10 % of the isolates showed this substitution in association with Ser416 to Ala in GyrB. The other amino acid changes found were characteristic of a few strains belonging to certain types and/or countries. Two new substitutions for C. difficile, Ser416 to Ala and Arg447 to Lys, were found in GyrB. Whereas the former does not seem to have a key role in resistance, since it was also detected in susceptible strains, the latter substitution occurred in the same position where other amino acid variations take place in resistant Escherichia coli and other C. difficile strains. A large number of C. difficile isolates now show an alarming pattern of resistance to the majority of FQs currently used in hospitals and outpatient settings, therefore judicious use of these antibiotics and continuous monitoring of in vitro resistance are necessary.

Abbreviations: CI, ciprofloxacin; FQs, fluoroquinolones; GA, gatifloxacin; LE, levofloxacin; MX, moxifloxacin; QRDR, quinolone-resistance determining region.

{dagger}Participating members of ESGCD were: F. Barbut, P. Mastrantonio, M. Delmée, J. S. Brazier, E. Kuijper, G. Ackermann, E. Bouza, C. Balmelli, D. Drudy, H. Ladas, E. Nagy, H. Pituch, M. Wullt, M. Yücesoy, M. Rupnik and I. R. Poxton.

The GenBank/EMBL/DDBJ accession numbers for the five new sequences for gyrA and four for gyrB are AM890062–AM890070.




This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
I. R. Poxton
Clostridium difficile
J. Med. Microbiol., June 1, 2008; 57(6): 683 - 684.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2008 Society for General Microbiology.